The information you provide to the chat will be collected and recorded to improve your experience and for quality assurance. Please read our privacy policy to see how we are storing and protecting your data.
How can we help you today?
ThermoFisher Scientific Patheon Pharma Services
×
Recent searches Clear History
Suggestions
All Results
 Search
 US | EN

Implications of inaccurate forecasting on biologics drug substance manufacturing

Whitepaper

Large molecule drug substance manufacturing and demand forecasting is riddled with complexity. The long cycle time and short shelf life of a biologic drug substance makes it difficult to adapt the supply chain with agility, even at the earliest stages of development. As a result, inaccurate demand forecasts can have significant implications for companies developing biologics. And with less industry-wide available capacity for biologic production, it is increasingly difficult to locate capacity to respond to demand changes and ensure products achieve commercial goals. Biopharma companies and their partner CDMOs are now implementing various measures to instill more flexibility into their manufacturing processes, including single-use parts, dual sourcing, and modular design.